latest IPO in India: Positive Surge – 5 Reasons to Watch Influx Healthtech Ltd 🧬
latest IPO in India Influx Healthtech Ltd is generating significant interest. With its debut on the NSE-SME platform in June 2025, the company’s SME-sized public issue offers investors a unique window into the burgeoning healthtech CDMO sector.
Company Overview
Influx Healthtech Ltd, founded in 2020 and headquartered in Mumbai, operates as a Contract Development & Manufacturing Organization (CDMO). It manufactures nutraceuticals, cosmetics, ayurvedic, veterinary, and homecare products across certified facilities in Thane covering ~36,000 sq ft.
IPO Timeline
- Open Date: 18 June 2025
- Close Date: 20 June 2025
- Basis of Allotment: 23 June 2025
- Refunds & Demat Credit: 24 June 2025
- Listing Date: 25 June 2025
Price Band
The IPO offers a price band of ₹91 to ₹96 per equity share (face value ₹10), representing 9.1–9.6× FV.
Lot Size
Each lot comprises 1,200 shares, with a minimum investment of ₹1,09,200–₹1,15,200 depending on the final price band.
Key Dates
- UPI Mandate Deadline: 20 June 2025, 5 PM
- Anchor Investor Lock-in: 50% for 30 days, balance 90 days post allotment
Financials
- FY25: Revenue ₹105 mn, PAT ₹13.4 mn, EBITDA ₹20.7 mn
- FY24: Revenue ₹100 mn, PAT ₹11.1 mn, EBITDA ₹17.0 mn
Strengths
- Certified facilities (GMP, HACCP, ISO, Halal, FDA)
- Diverse product range: nutraceuticals, veterinary, ayurvedic, more
- Led by experienced pharma professionals
Risks
- SME IPOs have higher volatility
- Short performance history makes valuation sensitive
- Highly competitive and regulated CDMO space
IPO Anchor Investors Details
| Investor Category | Shares Allocated | Percentage |
|---|---|---|
| Anchor Investors | 1,736,400 | 28.46% |
| QIBs | 1,159,200 | 19.00% |
| NIIs | 870,000 | 14.26% |
| RIIs | 2,029,200 | 33.26% |
IPO Promoter Holding Details
| Shareholder Group | Pre‑Issue Holding | Post‑Issue Holding |
|---|---|---|
| Promoter Group | 99.85% | 73.53% |
| Public Group | 0.15% | 26.47% |
IPO Grey Market Premium (GMP)
| Date | IPO GMP (₹) | GMP (%) |
|---|---|---|
| Mid‑June 2025 | ₹31 | 32.3% |
| Around issue time | ₹21–₹22 | ~22% |
IPO Subscription Status
Subscription data was pending at announcement. However, retail and institutional interest is expected to be strong given GMP and SME sentiment.
Final Thoughts
Influx Healthtech stands out as a promising SME IPO in the healthtech CDMO domain. With certified facilities, a strong product mix, and decent financial performance, it provides early investors a chance to ride the company’s growth trajectory. That said, valuation risk and SME volatility should be considered.
- Opportunities: High-growth sector, early entry
- Risks: Volatility, valuation sensitivity, regulatory challenges